DLL3 Recombinant Monoclonal Antibody

Code: CSB-RA882142MA2HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q9NYJ7

Target Names

DLL3

Alternative Names

Delta-like protein 3 (Drosophila Delta homolog 3) (Delta3), DLL3

Species Reactivity

Human

Immunogen

Recombinant Human DLL3 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

7B11

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

The Binding Activity of Human DLL3 with Anti-DLL3 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Human DLL3 (CSB-MP882142HU2d7) at 2 μg/mL can bind Anti-DLL3 recombinant antibody. The EC₅₀ is 3.990-4.723 ng/mL.
The Binding Activity of Human DLL3 with Anti-DLL3 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Human DLL3 (CSB-MP882142HU3) at 1 μg/mL can bind Anti-DLL3 recombinant antibody. The EC₅₀ is 6.080-7.240 ng/mL.
The Binding Activity of Human DLL3 with Anti-DLL3 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Human DLL3 (CSB-MP882142HU3d7) at 2 μg/mL can bind Anti-DLL3 recombinant antibody. The EC₅₀ is 1.107-1.282 ng/mL.
The Binding Activity of Human DLL3 with Anti-DLL3 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Human DLL3 (CSB-MP882142HU2) at 1 μg/mL can bind Anti-DLL3 recombinant antibody. The EC₅₀ is 6.211-7.209 ng/mL.
SHP-77 cells were stained with Human IgG1&Igκ Isotype Control (CSB-RA011156MA1HU)(green line) and anti-DLL3 antibody (CSB-RA882142MA2HU) (2µg/1*10⁶cells) (red line), washed and then followed by APC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
The purity of DLL3 was greater than 95% as determined by SEC-HPLC

Description

DLL3, or Delta-like protein 3, serves as a critical component of the Notch signaling pathway, functioning as an inhibitory ligand that modulates cell fate decisions during development. Unlike other Notch ligands, DLL3 is retained intracellularly where it regulates Notch receptor trafficking and signaling output. This unique expression pattern has generated significant research interest, particularly in neuroendocrine tumor biology where DLL3 shows highly restricted expression, making it a compelling target for both basic developmental studies and translational oncology research.

This recombinant monoclonal antibody, clone 7B11, offers the consistency and reproducibility that demanding experimental workflows require. Because recombinant antibodies are produced from defined sequences rather than hybridoma cultures, you can expect reliable performance across experiments and between lots, eliminating a common source of variability in longitudinal studies or multi-site collaborations.

Validation data demonstrates robust binding activity against human DLL3, with functional ELISA testing revealing EC50 values in the low nanogram per milliliter range across multiple antigen preparations, confirming high-affinity target recognition. Flow cytometry validation using SHP-77 cells, a human small cell lung cancer line, shows clear positive staining compared to isotype control, demonstrating the antibody's utility for detecting endogenous DLL3 expression on cell surfaces. For flow cytometry applications, dilutions between 1:50 and 1:200 provide an effective starting range for optimization.

Supplied as a purified liquid in a glycerol-PBS formulation, this antibody supports researchers investigating Notch pathway dynamics, neuroendocrine differentiation, and developmental signaling mechanisms. Whether you're characterizing DLL3 expression patterns or developing detection assays, this reagent provides a reliable foundation for your experimental design.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm.

Gene References into Functions

these results reveal that DLL3 is expressed in tumor specimens from most patients with small cell lung cancer PMID:29290251
Results indicated that DLL3 expression was silenced in hepatocellular carcinoma (HCC) cells by DNA methylation and was more readily affected by histone acetylation than histone methylation (H3K9me2 or H3K27me3). PMID:29512761
our results indicated epidermal growth factor-like domain multiple 7 protein participates in growth hormone-secreting pituitary adenoma proliferation and invasion regulation via Notch2/DLL3 signaling pathway. These findings raised the possibility that epidermal growth factor-like domain multiple 7 protein might serve as a useful biomarker to assess growth hormone-secreting pituitary adenoma invasion and prognosis PMID:28705113
The Dll3 was rarely detectable in the para-carcinoma tissues, but positive in 82.1% of non-small cell cancer tissues. PMID:28007595
Both global haplotype and individual haplotype analyses showed that the haplotypes of SNP1/SNP2/SNP3/SNP4/SNP5 did not correlate with the disease (P >0.05). Together, these data suggest that genetic variants of the DLL3 gene are not associated with CS in the Chinese Han population. PMID:27472720
DLL3 was silenced by methylation in human human hepatocellular carcinoma and it negatively regulates the growth of human hepatocellular carcinoma cells. PMID:23337976
We suggest that the three human DLL3 mutations associated with spondylocostal dysplasia are also functionally equivalent to the Dll3(neo) null allele in mice. PMID:11923214
mutations in DLL3 cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis PMID:12746394
no novel or previously described mutations are present in our cohort, indicating that DLL3 mutations may not be a major cause of congenital scoliosis. PMID:15717203
The intracellular region of Notch ligands Dll1 and Dll3 regulates their trafficking and signaling activity PMID:18676613